IMVEXXY Market Summary

Key Factors Driving IMVEXXY Growth

1. Large and Underdiagnosed GSM/VVA Patient Population

Genitourinary syndrome of menopause affects a substantial proportion of postmenopausal women. Published literature estimates that approximately 50% of postmenopausal women experience symptoms of vulvovaginal atrophy, including vaginal dryness, irritation, and dyspareunia. Despite the high prevalence, many women remain untreated or undertreated, creating a significant opportunity for therapies such as IMVEXXY. This large addressable patient base remains one of the product's most important growth drivers.

2. Lowest Approved Vaginal Estradiol Dose

IMVEXXY is differentiated as the only vaginal estradiol insert available in both 4 mcg and 10 mcg strengths, with the 4 mcg formulation representing the lowest FDA-approved vaginal estradiol dose. The availability of an ultra-low-dose estrogen option is attractive to physicians and patients seeking symptom relief while minimizing systemic estrogen exposure. Clinical studies submitted to the FDA showed systemic estradiol levels remained within the postmenopausal range during treatment.

3. Applicator-Free, Patient-Friendly Administration

A key commercial advantage of IMVEXXY is its applicator-free vaginal insert design. The product was specifically developed to improve convenience, ease of use, and patient satisfaction. The insert dissolves completely and does not require post-use cleanup. Convenience and patient preference are important factors in chronic menopausal therapies, where adherence often influences long-term prescription growth.

4. Geographic Expansion Beyond the United States

Growth is increasingly supported by international expansion. In January 2024, Knight Therapeutics launched IMVEXXY in Canada after receiving regulatory approval. The Canadian launch broadened the product's commercial footprint beyond the US market and provides a pathway for additional international growth through licensing partners.

5. Intellectual Property Protection Supporting Market Exclusivity

Mayne Pharma has actively defended IMVEXXY's intellectual property portfolio. According to company disclosures and litigation filings, IMVEXXY is protected by numerous US patents, with protection extending into the next decade. Patent protection delays generic competition and helps preserve pricing power and market share. In 2024, Mayne Pharma initiated patent litigation following a generic challenge from Sun Pharmaceutical Industries, underscoring the commercial value of the franchise.

 

6. Continued Growth Within Mayne Pharma's Women's Health Portfolio

Mayne Pharma has repeatedly highlighted IMVEXXY as part of its growing women's health business. The company reported that IMVEXXY revenue reached approximately USD 10.8 million during the first half of FY2024, representing roughly 29% year-over-year growth. Management has also described IMVEXXY as a contributor to the steady expansion of its broader women's health portfolio. This demonstrates continued prescription demand several years after launch.

IMVEXXY Recent Developments

In December 2025, The US Food and Drug Administration approved the first generic version of IMVEXXY (estradiol vaginal inserts). This approval will provide women additional options for access to treatment of moderate to severe dyspareunia (painful sexual intercourse), a symptom of vulvar and vaginal atrophy, due to menopause by delivering a low dose of estradiol directly to vaginal tissue.

 

“IMVEXXY Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of IMVEXXY for approved indication like Atrophic vaginitis in the 7MM. A detailed picture of IMVEXXY’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the IMVEXXY for approved indications. The IMVEXXY market report provides insights about IMVEXXY’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IMVEXXY performance, future market assessments inclusive of the IMVEXXY market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IMVEXXY sales forecasts, along with factors driving its market.

IMVEXXY Drug Summary

IMVEXXY is a prescription, locally administered bioidentical estradiol vaginal insert approved for the treatment of moderate-to-severe dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy associated with menopause, now commonly referred to as genitourinary syndrome of menopause (GSM). Developed by Therapeutics MD and marketed in the United States, IMVEXXY contains ultra-low-dose estradiol (4 mcg or 10 mcg) delivered via a soft gel vaginal insert designed for minimal systemic estrogen exposure while effectively restoring vaginal tissue health. Estradiol acts by binding estrogen receptors in the vaginal epithelium, improving tissue thickness, elasticity, lubrication, and pH, thereby alleviating symptoms such as vaginal dryness, irritation, and painful intercourse. The product is administered daily for the first two weeks followed by twice-weekly maintenance dosing and has demonstrated significant improvements in dyspareunia severity, vaginal cytology, and vaginal pH in pivotal clinical trials. Its convenient applicator-free administration, low systemic absorption, and favorable safety profile have made IMVEXXY an important treatment option for postmenopausal women seeking localized estrogen therapy for GSM. The report provides IMVEXXY’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the IMVEXXY Market Report

The report provides insights into:

• A comprehensive product overview including the IMVEXXY MoA, description, dosage and administration, research and development activities in approved indication like Atrophic vaginitis.

• Elaborated details on IMVEXXY regulatory milestones and other development activities have been provided in IMVEXXY market report.

• The report also highlights IMVEXXY‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.

• The IMVEXXY market report also covers the patents information, generic entry and impact on cost cut.

• The IMVEXXY market report contains current and forecasted IMVEXXY sales for approved indications till 2034.

• Comprehensive coverage of the late-stage emerging therapies for respective indications.

• The IMVEXXY market report also features the SWOT analysis with analyst views for IMVEXXY in approved indications.

Methodology

The IMVEXXY market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

IMVEXXY Analytical Perspective by DelveInsight

• In-depth IMVEXXY Market Assessment

This IMVEXXY sales market forecast report provides a detailed market assessment of IMVEXXY for approved indication like Atrophic vaginitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IMVEXXY sales data uptil 2034.

• IMVEXXY Clinical Assessment

The IMVEXXY market report provides the clinical trials information of IMVEXXY for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

IMVEXXY Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

IMVEXXY Market Potential & Revenue Forecast

• Projected market size for the IMVEXXY and its key indications

• Estimated IMVEXXY sales potential (IMVEXXY peak sales forecasts)

• IMVEXXY Pricing strategies and reimbursement landscape

IMVEXXY Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)

• IMVEXXY Market positioning compared to existing treatments

• IMVEXXY Strengths & weaknesses relative to competitors

IMVEXXY Regulatory & Commercial Milestones

• IMVEXXY Key regulatory approvals & expected launch timelines

• Commercial partnerships, licensing deals, and M&A activity

IMVEXXY Clinical Differentiation

• IMVEXXY Efficacy & safety advantages over existing drugs

• IMVEXXY Unique selling points

 

IMVEXXY Market Report Highlights

• In the coming years, the IMVEXXY market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.

• The IMVEXXY companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMVEXXY’s dominance.

• Other emerging products for Atrophic vaginitis are expected to give tough market competition to IMVEXXY and launch of late-stage emerging therapies in the near future will significantly impact the market.

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMVEXXY in approved indications.

• Analyse IMVEXXY cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.

• Our in-depth analysis of the forecasted IMVEXXY sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IMVEXXY in approved indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of IMVEXXY? How strong is IMVEXXY’s clinical and commercial performance?

• What is IMVEXXY’s clinical trial status in each individual indications such as Atrophic vaginitis and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMVEXXY Manufacturers?

• What are the key designations that have been granted to IMVEXXY for approved indications? How are they going to impact IMVEXXY’s penetration in various geographies?

• What is the current and forecasted IMVEXXY market scenario for approved indications? What are the key assumptions behind the forecast?

• What are the current and forecasted sales of IMVEXXY in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?

• What are the other emerging products available and how are these giving competition to IMVEXXY for approved indications?

• Which are the late-stage emerging therapies under development for the treatment of approved indications?

• How cost-effective is IMVEXXY? What is the duration of therapy and what are the geographical variations in cost per patient?